Healthcare-Acquired Infections: Devices, Pharmaceuticals, and Environmental Products

The global market for healthcare-acquired infection (HCAI) control should grow from $18.9 billion in 2018 to $24.7 billion by 2023 at a compound annual growth rate (CAGR) of 5.4% from 2018 through 2023.

Report Includes

• 42 data tables and 32 additional tables
• Industry analysis of the global healthcare-acquired infection (HCAI) control market
• Detailed overview and trend analysis of pharmaceutical treatment (antimicrobials and vaccines), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (catheters, patient ventilation devices, sterile intravenous [IV] filters) that prevent these infections
• Analyses of global market trends with data from 2017, estimates for 2018 and projections of compound annual growth rates (CAGRs) through 2023
• Emphasis on selected devices, pharmaceuticals and environmental products currently employed or under development for treatment of viral, bacterial and fungal infections
• Analysis of antimicrobial resistance and more specifically antibiotic resistance as a cause for these infections
• A look at the hospital surveillance methods and tools currently being used to prevent these infections
• Regional analysis of the market covering Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, Russia and Africa); and Asia-Pacific (i.e. Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries)
• Information on key patents and newer research developments in sterilization systems and devices
• Examination of vendor landscape and profiles of key players in the HCAI market, including Novartis, Pfizer, Roche, 3M Healthcare and Sanofi Pasteur

The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.

Report Includes

• Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections
• Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020
• Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry
• Information needed to understand the current market and to address the emerging market.

The global market for selected HAI treatments was nearly $12.1. billion in 2012. The market is expected to reach $14.0 billion in 2013 and nearly $20.8 billion in 2018 with a compound annual growth rate (CAGR) of 8.2%.

Report Includes

• Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry
• Background on the structure of the HAI market and the opportunities available as well as the chief challenges it faces
• Information needed to understand the current market and to address the emerging market
• Comprehensive company profiles of key players in the market.

The global market for healthcare-acquired infection treatments were nearly $16 billion in year 2010. This market is estimated to be around $18.3 billion in the year 2011 and is forecasted to reach $25.6 billion by 2016 at a CAGR of 7.0% for five year period.